An Open Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-term on Mycophenolate Mofetil (MMF) (CellCept) and Sirolimus (Rapamune).

Trial Profile

An Open Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-term on Mycophenolate Mofetil (MMF) (CellCept) and Sirolimus (Rapamune).

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2011

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Ciclosporin; Corticosteroids; Sirolimus; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms STN
  • Sponsors Roche
  • Most Recent Events

    • 01 Apr 2011 Results published in Kidney International.
    • 23 Feb 2011 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov. (NCT00121810).
    • 23 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov. (NCT00121810).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top